An antibody to PlGF, a ligand of VEGFR1, but not VEGFR2, is highly effective at suppressing tumor angiogenesis and choroidal neovascularization (CNV) in an experimental model of AMD and its efficacy is enhanced when used in combination with an antibody to VEGFR2, providing evidence that both receptors play a role [28]. The gene discussed is KDR; the disease is age-related macular degeneration.